Anticancer Research · 2019 · 38 citations · 29 references
MedicineOncologyPharmacologyCancer PharmacologyCell ProliferationMolecular OncologyCancer Cell SignalingColorectal CancerGastrointestinal Cancer PharmacotherapyMalignant NeoplasmsOncology NutritionTumor PromotionAnticancer ActivityCancer Cell Proliferation InhibitionColorectal Cancer Chemoprevention
BACKGROUND/AIM: Fatty acid synthase (FASN) provides palmitate for cell membrane formation in colorectal cancer (CRC) cells, however, palmitate is also available in the blood of CRC patients. The aim of this study was to examine whether orlistat, a FASN inhibitor, is able to attenuate CRC cell growth despite the availability of extracellular palmitate. MATERIALS AND METHODS: Palmitate concentrations were measured in serum from CRC patients and healthy controls. HT-29 CRC cells were treated with orlistat and palmitate. RESULTS: Treatment of CRC cells with orlistat caused a dose-dependent inhibition of cell proliferation. In turn, delivery of extracellular palmitate at doses lower than those found in the serum of CRC patients reversed inhibition by orlistat concentrations of up to 10 μM. CONCLUSION: Inhibition of CRC cell proliferation by orlistat is reversed by palmitate which is present at high levels in the serum. Therefore, orlistat may be effective in vivo only at high concentrations.
29
Rungtawan Sriburi, Suzanne Jackowski, Kazutoshi Mori et al. · The Journal of Cell Biology · 2004 · 649 citations · Full text
Orlistat Is a Novel Inhibitor of Fatty Acid Synthase with Antitumor Activity
Steven J. Kridel, Fumiko Axelrod, Natasha Rozenkrantz et al. · Cancer Research · 2004 · 601 citations · Full text
Medicine, Oncology, Pharmacology +16
Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer
Junjie Li, Dongsheng Gu, S S-Y Lee et al. · Oncogene · 2016 · 308 citations · Full text
Medicine, Cancer Biology, Oncology +17